Table 2 Characteristics of the all 38 retreated patients with oral antiviral agents
Characteristics | Total (n = 38) | Initial HBeAg-positive (n = 31) | Initial HBeAg- negative (n = 7) |
|---|---|---|---|
At the time of retreatment | |||
ALT (IU/L) | 264 (81-895) | 233 (83-895) | 311 (81-575) |
  >2 x and ≤10 x ULN, n (%) | 26 (68.4) | 21 (67.7) | 5 (71.4) |
  >10 x ULN, n (%) | 12 (31.6) | 10 (32.3) | 2 (28.6) |
HBV DNA (Log10copies/mL) | 8.1 (5.3-9.7) | 8.1 (5.3-9.7) | 8.0 (5.8-8.9) |
Time to hepatitis flare (months) * | 8 (3-29) | 7 (3-21) | 18 (6-29) |
Follow-up after cessation (months) | 29 (2-43) | 28 (2-43) | 30 (3-42) |
At the last follow-up after retreatment | |||
ALT normalization, n (%) | 37 (97.4) | 31 (100) | 6 (85.7) |
Time to ALT normalization (months) | 4 (1-21) | 4 (1-21) | 3 (3-26) |
Serum HBV DNA level, n (%) | |||
  <50 copies/mL | 24 (63.2) | 19 (61.3) | 5 (71.4) |
  50-104 copies/mL | 11 (28.9) | 9 (29.0) | 2 (28.6) |
  ≥104 copies/mL | 3 (7.9) | 3 (9.7) | 0 |
Time to serum HBV DNA level (months) | |||
  <50 copies/mL | 10 (3-33) | 12 (1-33) | 9 (3-26) |
  50-104 copies/mL | 8 (1-31) | 8 (1-31) | 11 (3-26) |
Hospitalization, n (%) | 1 (2.6) | 1 (3.2) | 0 (0) |
Retreatment drugs: | |||
  ETV/LAM/CLV/ADV, n (%) | 30/4/3/1 | 27/2/2/0 | 3/2/1/1 |
| Â | (78.9/10.5/7.9/2.6) | (87.1/6.5/6.5/0) | (42.9/28.6/14.3/14.3) |
Follow-up after retreatment (mo) | 18 (2-39) | 18 (2-39) | 17 (6-33) |